Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis.
By using immunohistochemistry we investigated the expression of EphA2 and EphrinA-1 in 217 early squamous cell cervical carcinomas and examine their prognostic relevance. For EphA2 expression, 21 tumors (10%) showed negative, 108 (50%) weak positive, 69 (32%) moderate positive and 19 (9%) strong positive, whereas for EphrinA-1 expression, 33 tumors (15%) showed negative, 91 (42%) weak positive, 67 (31%) moderate positive and 26 (12%) strong positive. In univariate analysis high expression (strong staining) of EphrinA-1 was associated with poor disease-free (P = 0.033) and disease-specific (P = 0.039) survival. However, in the multivariate analyses neither EphrinA-1 nor EphA2 was significantly associated to survival. The increased levels of EphA2 and EphrinA-1 in a relative high number of early stage squamous cell carcinomas suggested that these two proteins may play an important role in the development of a subset of early cervical cancers. However, EphA2 and EphrinA-1 were not independently associated with clinical outcome.
Division of Pathology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway. ruth.holm@radiumhospitalet.no
Ruth
R
Holm
Gregg Van
GV
de Putte
Zhenhe
Z
Suo
A Kathrine
AK
Lie
Gunnar B
GB
Kristensen
D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality; D018572:Disease-Free Survival; D036382:Ephrin-A1 / Q000096:biosynthesis*; D036383:Ephrin-A2 / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008875:Middle Aged; D008954:Models, Biological; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000401:mortality
D036382:Ephrin-A1; D036383:Ephrin-A2